Ngm Biopharmaceuticals Inc

NASDAQ:NGM  
5.37
+0.04 (+0.75%)
3:07:25 PM EDT: $5.38 +0.01 (+0.19%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)442.16M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.76 Million
Adjusted EPS-$0.52
See more estimates
10-Day MA$5.39
50-Day MA$8.34
200-Day MA$13.17
See more pivots

Ngm Biopharmaceuticals Inc Stock, NASDAQ:NGM

333 Oyster Point Boulevard, South San Francisco, California 94080-7014
United States of America
Phone: +1.650.243.5555
Number of Employees: 225

Description

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.